Avidity Biosciences, Inc. — Director's Dealing 2021

Nov 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2021-11-18

Reporting Person: LEVIN ARTHUR A (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-18	Common Stock	M	24396	$1.24	Acquired	25726	Direct
2021-11-18	Common Stock	M	604	$0.53	Acquired	26330	Direct
2021-11-18	Common Stock	S	25000	$27.8887	Disposed	1330	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-18	Stock Option (Right to Buy)	$1.24	M	24396	Disposed	2030-02-18	Common Stock (24396)	Direct
2021-11-18	Stock Option (Right to Buy)	$0.53	M	604	Disposed	2027-08-28	Common Stock (604)	Direct

Footnotes

F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.75 to $28.2150.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.

F4: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.